Showing results (51-60 of 66) with videos related to

Sort By:
Pageof 7
American Journal of Hematology|June 20, 2024
Outcomes of acute myeloid leukemia patients who responded to venetoclax and azacitidine and stopped treatmentSylvain Garciaz, Pierre-Yves Dumas, Sarah Bertoli, et al.
Cancer Medicine|December 9, 2022
Retrospective, real-life study of venetoclax plus azacitidine or low-dose cytarabine in French patients with acute myeloid leukemia ineligible for intensive chemotherapyLouise Laloi, Natacha Chaumard Billotey, Pierre-Yves Dumas, et al.
Leukemia|September 18, 2020
Lomustine is beneficial to older AML with ELN2017 adverse risk profile and intermediate karyotype: a FILO studyLaetitia Largeaud, Pascale Cornillet-Lefebvre, Jean-François Hamel, et al.
Blood|December 12, 2022
Overlapping features of therapy-related and de novo NPM1-mutated AMLJad Othman, Manja Meggendorfer, Enrico Tiacci, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 31, 2025
Clonal Evolution of PPM1D Mutations in the Spectrum of Myeloid DisordersDavid Fandrei, Jean Pegliasco, Florence Pasquier, et al.
American Journal of Hematology|February 11, 2026
Intensive Chemotherapy With or Without Midostaurin in Adults ≥ 60 Years Old With FLT3-Mutated AML: A FILO-DATAML-PETHEMA Real-World StudyGaspar Aspas Requena, Pau Montesinos, Emilie Bérard, et al.
Haematologica|April 2, 2026
Hypomethylating agents plus venetoclax versus intensive chemotherapy prior to transplant in high-risk acute myeloid leukemiaGuillaume Berton, Jan Philipp Bewersdorf, Julia Gilhodes, et al.
Blood|September 2, 2020
A personalized approach to guide allogeneic stem cell transplantation in younger adults with acute myeloid leukemiaLaurène Fenwarth, Xavier Thomas, Stéphane de Botton, et al.
NEJM Evidence|June 24, 2025
Intermediate-Dose Cytarabine as Postinduction AML TherapyMathilde Hunault, Cécile Pautas, Sarah Bertoli, et al.
Leukemia|May 12, 2026
Comprehensive mutational profiling and clinical outcome of adult acute myeloid leukemia patients with NUP98 rearrangementBenoit Ducourneau, Arnaud Pages, Stéphanie Struski, et al.
Pageof 7